Cargando…
Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
BACKGROUND: Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are a favourable option for patients with migraine who experience distressful headache disability and fail to respond to traditional preventive treatment options. However, since CGRPmAb has been available for only 2 ye...
Autores principales: | Ihara, Keiko, Ohtani, Seiya, Watanabe, Narumi, Takahashi, Nobuyuki, Miyazaki, Naoki, Ishizuchi, Kei, Hori, Satoko, Takemura, Ryo, Nakahara, Jin, Takizawa, Tsubasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996919/ https://www.ncbi.nlm.nih.gov/pubmed/36890436 http://dx.doi.org/10.1186/s10194-023-01556-7 |
Ejemplares similares
-
Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
por: Ohtani, Seiya, et al.
Publicado: (2023) -
Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
por: Takizawa, Tsubasa, et al.
Publicado: (2022) -
Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study
por: Sekiguchi, Koji, et al.
Publicado: (2021) -
Migraine triggers in Asian countries: a narrative review
por: Iba, Chisato, et al.
Publicado: (2023) -
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)